Last updated: February 13, 2026
What Is the Drug?
NDC 58151-0127 refers to Trelegy Ellipta, an inhalation powder indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma. Produced by GlaxoSmithKline, Trelegy Ellipta combines three active ingredients: fluticasone furoate, umeclidinium, and vilanterol.
Market Size and Demand
Global COPD and Asthma Treatment Market
- The global COPD market was valued at approximately $9.7 billion in 2022, expected to reach $15 billion by 2030, with a compound annual growth rate (CAGR) of 6.4% (source: MarketsandMarkets).
- The asthma management segment accounted for roughly $7 billion in 2022, with steady growth driven by increasing prevalence and improved diagnosis rates.
Key Market Drivers
- Rising COPD prevalence: Estimated 200 million cases worldwide.
- Aging population: COPD and asthma are more common in older adults.
- Increasing disease awareness and diagnosis.
- Advancements in inhaler devices improving patient adherence.
Market Competition
Trelegy Ellipta competes with other triple-inhaler combinations, including AstraZeneca’s Breztri Aerosphere and other single- and combination therapy inhalers.
Current Pricing Landscape
Current List Price
- As of Q1 2023, the average wholesale price (AWP) for Trelegy Ellipta ranges from $400 to $430 per inhaler.
- A typical prescription involves a 30-day supply, or approximately 30 inhalations.
Reimbursement and Insurance Coverage
- Commercial insurance and Medicare Part D generally cover Trelegy with patient copayments between $10 and $50.
- Discount programs and patient assistance reduce effective costs.
Price Trends and Projections
| Year |
Estimated AWP per Inhaler |
Notes |
| 2023 |
$400 – $430 |
Baseline for current pricing |
| 2025 |
$410 – $440 |
Anticipated minor increases due to inflation |
| 2030 |
$440 – $480 |
Driven by inflation, R&D costs, and market dynamics |
Factors Influencing Price Trends:
- Regulatory changes: Potential for price regulation or discounts.
- Patent status: Patent expiration or biosimilar entry could lead to price reductions. The patent for Trelegy Ellipta was granted in 2018 and expected to last until at least 2030, providing market exclusivity until then.
- Market adoption: Increased prescribing volume may somewhat offset price pressures.
- Manufacturing costs: Rising costs could influence pricing.
Future Market Penetration and Revenue Outlook
- Expected to maintain or slightly increase market share through expanded indications and payer coverage.
- Projected global sales of Trelegy Ellipta may reach $2 billion annually by 2030, assuming continued growth and competition management (source: IQVIA).
Strategic Considerations for Stakeholders
- Investors: The drug’s patent lifecycle and the intensity of generic competition after expiration are critical.
- Pharma companies: Potential for value-based pricing models as payers seek cost-effective COPD management.
- Healthcare providers: Increased emphasis on adherence features and combination therapies can affect prescribing patterns.
Key Takeaways
- NDC 58151-0127 (Trelegy Ellipta) is a leading triple combination inhaler for COPD and asthma.
- Market size is driven by increasing COPD prevalence, aging populations, and advancements in inhalation therapy.
- Current list prices for inhalers average $400–$430, with slight increases projected.
- Patent protection provides exclusivity until about 2030; post-expiration, prices may decline due to biosimilar competition.
- Revenue projections suggest continued growth to approximately $2 billion globally by 2030, contingent on market dynamics.
FAQs
Q1. When will Trelegy Ellipta face generic competition?
A1. The patent is expected to expire around 2029–2030, enabling potential generic entrants.
Q2. How do rebate programs influence actual patient costs?
A2. Rebate programs and formulary positioning can reduce the effective patient copay from the list price, sometimes by over 70%.
Q3. Is there potential for price reductions post-patent expiry?
A3. Yes, generic competitors typically lower prices, often by 40–60%, affecting the overall market.
Q4. How does Trelegy Ellipta compare with competitors?
A4. It has a unique triple-combination formulation with high patient adherence due to once-daily dosing, maintaining a competitive edge until patent expiry.
Q5. What innovations could influence future pricing?
A5. Delivery device improvements, digital health integrations, and personalized medicine approaches could modify value propositions and pricing strategies.
References
- MarketsandMarkets. COPD therapeutics market report 2022–2030.
- IQVIA. Global pharmaceutical sales data 2022.
- FDA. Patent information and exclusivity timelines.
- AWP data sources (GoodRx, Elsevier Gold Standard) 2023.
